A Case of Cutaneous B‐cell Lymphoma Treated Successfully with MACOP‐B

Nagatani, Tetsuya; Miyazawa, Megumi; Matsuzaki, Toshiko; Hayakawa, Hisao; Iemoto, Gaijiro; Kim, Shutaku; Baba, Naoko; Sugiyama, Asami; Aihara, Michiko; Miyamoto, Hideaki; Nakajima, Hiroshi; Katakura, Hitoshi

doi:10.1111/j.1346-8138.1993.tb03827.x

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CHOP regimen appears to be preferred to COP as it reduces relapse rates (43). A case has been successfully treated with MACOP‐B polychemoterapy showing a good response and a DFS of more than 3 yr (45). Even the systemic administration of rituximab appears a good chance, in particular, in the elderly; in very aggressive or in plurirelapsing lymphomas, in case with systemic involvement, the combination of rituximab with anthracycline‐containing chemotherapies may be proposed, even if data about response and prolonged follow‐up are still lacking (17, 31).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B‐cell lymphomas and comparison with the commonly used therapies

Pulini¹,

Rupoli²,

Goteri³

et al. 2009

European J of Haematology

View full text Add to dashboard Cite

Doxorubicin is frequently used in the treatment of lymphomas; the pegylated liposomal formulation of the drug (Peg-Doxo) has significantly improved its therapeutic index, reducing the toxic adverse effects. Peg-Doxo shows a similar efficacy, being less cardiotoxic, producing less nausea and vomiting and only mild myelosuppression and alopecia (1). The drug, carried in stealth liposomes able to escape the interception by the immune system, shows a prolonged circulation time and a propensity for extravasating through the leaky vessels of the tumour tissues; it results the increased concentration of the drug in target tissues and the decreased toxicity to normal cells (2). Originally approved for the treatment of metastatic breast cancer, in advanced ovarian cancer and in Kaposi's sarcoma, Peg-Doxo has AbstractObjectives: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primary cutaneous T-cell lymphomas, while in primary cutaneous B-cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far. Methods: We performed a prospective phase II pilot clinical trial of Peg-Doxo monotherapy (20 mg ⁄ m 2 ) in PCBCLs. One patient had a marginal zone B-cell lymphoma and four were affected by diffuse large B-cell lymphoma-leg type, all with widespread nodular lesions. Results: All the patients achieved a complete response (CR = 100%) in a short period of time (median 3 months), even when pretreated with radio-chemotherapy. Two experienced a relapse. At follow-up, one patient died for progressive disease; four are in CR after 5, 52, 63 and 69 months. As concerning the toxicity profile, the treatment was well-tolerated, no one decreased or delayed the dose. The haematological toxicity was mild with only one case of grade III neutropenia; a patient showed a grade I neurotoxicity. Dermatological toxicity, in particular the palmarplantar erythrodysesthesia, did not occurred, probably because of both the low dosages of Peg-Doxo monotherapy and the oral prophylaxis with pyridoxine. Conclusions: In spite of the small number of patients, it emerges that monochemotherapy with Peg-Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed. It suggests the need of further investigations in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B‐cell lymphomas and comparison with the commonly used therapies

Pulini¹,

Rupoli²,

Goteri³

et al. 2009

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Patients with leg or widespread lesions showed a higher relapse rate (55 vs. 26%) than those with trunk or head lesions. The use of another type of chemotherapy, that is MACOP‐B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin), has been reported in one case with a good clinical response and a disease‐free interval for more than 3 years 11 …”

Section: Different Methods Of Treatmentmentioning

confidence: 99%

Standard and new treatments in cutaneous B‐cell lymphomas

Dréno

2006

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…Eine Chemotherapie (6 Zyklen ᭤ CHOP, COP, MACOP) kann zur Regression (PR, CR) des Befundes führen [8,15,16] und sollte unter nachfolgender Anwendung von Interferon a2a (3×3 Mio IE pro Woche) oder Anti-CD20-Antikörper Rituximab als Erhaltungstherapie stabilisiert werden. Eine Chemotherapie (6 Zyklen ᭤ CHOP, COP, MACOP) kann zur Regression (PR, CR) des Befundes führen [8,15,16] und sollte unter nachfolgender Anwendung von Interferon a2a (3×3 Mio IE pro Woche) oder Anti-CD20-Antikörper Rituximab als Erhaltungstherapie stabilisiert werden.…”

Section: Systemische Therapieunclassified

Kutane B-Zell-Lymphome

et al. 2000

View full text Add to dashboard Cite

LernzielPrimär kutane B-Zell-Lymphome (PCBCL) gehören zur Gruppe der Non-Hodgkin-Lymphome. Die Klassifikation erfolgt entsprechend dem Konsens der EORTC. Ziel dieses Artikels ist es, die wesentlichen klinischen Manifestationsformen und ihre entsprechenden histologischen Merkmale zu vermitteln: häufiger vorkommendes, histologisch vom Typ des Keimzentrumszell-Lymphoms, prognostisch günstiges B-Zell-Lymphom am Stamm und Kopf sowie selten zu diagnostizierendes, prognostisch ungünstiges großzelliges B-Zell-Lymphom der unteren Extremität. Es werden Empfehlungen zum einheitlichen Vorgehen in Staging und Diagnostik gegeben. Die Behandlungsmöglichkeiten der PCBCL sind vielfältig und sollten sich an den klinischen Entitäten sowie deren Prognose orientieren. Sie reichen von Exzision über Radiotherapie und Chemotherapie (CHOP) bis zu Immuntherapien (IFNα2a, IL2, Rituximab).Hautarzt 2000 · 51:363-375 © Springer-Verlag 2000 Redaktion Prof.Dr.P.Fritsch, Innsbruck Prof.Dr.W.Vanscheidt, Freiburg Die Beiträge der Rubrik Weiterbildung sollen dem Stand des zur Facharztprüfung für den Hautarzt ohne Schwerpunktbezeichnung notwendigen Wissens entsprechen und zugleich dem niedergelassenen Facharzt als Repititorium dienen.Die Rubrik beschränkt sich auf klinisch gesicherte Aussagen zum Thema.

show abstract

A Case of Cutaneous B‐cell Lymphoma Treated Successfully with MACOP‐B

Cited by 7 publications

References 12 publications

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B‐cell lymphomas and comparison with the commonly used therapies

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B‐cell lymphomas and comparison with the commonly used therapies

Standard and new treatments in cutaneous B‐cell lymphomas

Kutane B-Zell-Lymphome

Contact Info

Product

Resources

About